PMID- 37258706
OWN - NLM
STAT- MEDLINE
DCOM- 20231228
LR  - 20240306
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 181
IP  - 2
DP  - 2024 Jan
TI  - Targeting integrins in drug-resistant acute myeloid leukaemia.
PG  - 295-316
LID - 10.1111/bph.16149 [doi]
AB  - Acute myeloid leukaemia (AML) continues to have a poor prognosis, warranting new 
      therapeutic strategies. The bone marrow (BM) microenvironment consists of niches 
      that interact with not only normal haematopoietic stem cells (HSC) but also 
      leukaemia cells like AML. There are many adhesion molecules in the BM 
      microenvironment; therein, integrins have been of central interest. AML cells 
      express integrins that bind to ligands in the microenvironment, enabling adhesion 
      of leukaemia cells in the microenvironment, thereby initiating intracellular 
      signalling pathways that are associated with cell migration, cell proliferation, 
      survival, and drug resistance that has been described to mediate cell 
      adhesion-mediated drug resistance (CAM-DR). Identifying and targeting integrins 
      in AML to interrupt interactions with the microenvironment have been pursued as a 
      strategy to overcome CAM-DR. Here, we focus on the BM microenvironment and review 
      the role of integrins in CAM-DR of AML and discuss integrin-targeting strategies. 
      LINKED ARTICLES: This article is part of a themed issue on Cancer 
      Microenvironment and Pharmacological Interventions. To view the other articles in 
      this section visit 
      http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.2/issuetoc.
CI  - (c) 2023 The Authors. British Journal of Pharmacology published by John Wiley & 
      Sons Ltd on behalf of British Pharmacological Society.
FAU - Ogana, Heather A
AU  - Ogana HA
AUID- ORCID: 0000-0002-1541-3698
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Hurwitz, Samantha
AU  - Hurwitz S
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Wei, Nathan
AU  - Wei N
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Lee, Eliana
AU  - Lee E
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Morris, Kayla
AU  - Morris K
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Parikh, Karina
AU  - Parikh K
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
FAU - Kim, Yong-Mi
AU  - Kim YM
AD  - Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology 
      and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, 
      University of Southern California, Los Angeles, California, USA.
LA  - eng
GR  - R01 CA172896/CA/NCI NIH HHS/United States
GR  - CA172896/NH/NIH HHS/United States
GR  - CA172896/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230619
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Integrins)
RN  - 0 (Cell Adhesion Molecules)
SB  - IM
MH  - Humans
MH  - *Integrins/metabolism
MH  - *Leukemia, Myeloid, Acute/drug therapy/metabolism
MH  - Bone Marrow/metabolism
MH  - Hematopoietic Stem Cells
MH  - Cell Adhesion Molecules/metabolism
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - acute myeloid leukaemia
OT  - bone marrow microenvironment
OT  - cell adhesion molecules
OT  - cell adhesion-mediated chemoresistance
OT  - integrins
OT  - leukaemia stem cells
OT  - therapy
EDAT- 2023/06/01 01:08
MHDA- 2023/12/28 06:42
CRDT- 2023/05/31 23:27
PHST- 2023/04/14 00:00 [revised]
PHST- 2023/01/10 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/12/28 06:42 [medline]
PHST- 2023/06/01 01:08 [pubmed]
PHST- 2023/05/31 23:27 [entrez]
AID - 10.1111/bph.16149 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2024 Jan;181(2):295-316. doi: 10.1111/bph.16149. Epub 2023 Jun 
      19.